Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Quest Partners LLC

Quest Partners LLC lowered its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 33.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,146 shares of the company’s stock after selling 3,028 shares during the period. Quest Partners LLC’s holdings in Nurix Therapeutics were worth $128,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Redmile Group LLC raised its holdings in Nurix Therapeutics by 37.7% in the first quarter. Redmile Group LLC now owns 4,483,016 shares of the company’s stock valued at $65,900,000 after buying an additional 1,226,497 shares during the period. Candriam S.C.A. increased its stake in Nurix Therapeutics by 30.5% during the second quarter. Candriam S.C.A. now owns 1,164,246 shares of the company’s stock valued at $24,297,000 after purchasing an additional 272,136 shares during the last quarter. Affinity Asset Advisors LLC grew its position in shares of Nurix Therapeutics by 17.4% during the 1st quarter. Affinity Asset Advisors LLC now owns 810,253 shares of the company’s stock valued at $11,911,000 after buying an additional 120,141 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Nurix Therapeutics by 9.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 622,297 shares of the company’s stock worth $6,422,000 after buying an additional 53,721 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its stake in Nurix Therapeutics by 73.5% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 434,413 shares of the company’s stock valued at $6,386,000 after acquiring an additional 184,086 shares in the last quarter.

Nurix Therapeutics Stock Performance

Shares of NRIX opened at $25.44 on Tuesday. The firm has a market cap of $1.25 billion, a PE ratio of -8.71 and a beta of 2.23. The firm’s 50 day moving average price is $22.70 and its 200 day moving average price is $18.02. Nurix Therapeutics, Inc. has a twelve month low of $4.22 and a twelve month high of $26.12.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Thursday, July 11th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.08). Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. The company had revenue of $12.09 million for the quarter, compared to the consensus estimate of $19.35 million. On average, sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on NRIX shares. Truist Financial initiated coverage on shares of Nurix Therapeutics in a research note on Wednesday, July 31st. They set a “buy” rating and a $36.00 target price on the stock. HC Wainwright upped their price target on shares of Nurix Therapeutics from $19.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, June 18th. Piper Sandler restated an “overweight” rating and issued a $35.00 price target on shares of Nurix Therapeutics in a research report on Wednesday, June 5th. Oppenheimer raised their price objective on Nurix Therapeutics from $27.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 4th. Finally, JPMorgan Chase & Co. upped their price target on shares of Nurix Therapeutics from $31.00 to $34.00 and gave the company an “overweight” rating in a research report on Monday, July 15th. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, Nurix Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.00.

Insiders Place Their Bets

In related news, CFO Houte Hans Van sold 20,000 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $25.22, for a total transaction of $504,400.00. Following the transaction, the chief financial officer now owns 31,002 shares of the company’s stock, valued at $781,870.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,408 shares of the company’s stock in a transaction that occurred on Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total value of $70,443.36. Following the completion of the transaction, the insider now owns 45,150 shares of the company’s stock, valued at approximately $933,250.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Houte Hans Van sold 20,000 shares of Nurix Therapeutics stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $25.22, for a total value of $504,400.00. Following the sale, the chief financial officer now directly owns 31,002 shares in the company, valued at approximately $781,870.44. The disclosure for this sale can be found here. Insiders sold a total of 59,815 shares of company stock valued at $1,416,751 in the last quarter. Insiders own 7.20% of the company’s stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.